Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Dec 31;5(12):e15298.
doi: 10.1371/journal.pone.0015298.

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

Hideyuki Sawada  1 , Tomoko Oeda, Sadako Kuno, Masahiro Nomoto, Kenji Yamamoto, Mitsutoshi Yamamoto, Kinya Hisanaga, Takashi Kawamura; Amantadine Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

Hideyuki Sawada et al. PLoS One. .

Abstract

Background: Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease. The purpose of the present study was to investigate the efficacy of amantadine in Parkinson's disease patients suffering from dyskinesias.

Methods: In this multi-center, double-blind, randomized, placebo-controlled, cross-over trial, 36 patients with Parkinson's disease and dyskinesias were randomized, and 62 interventions, which included amantadine (300 mg/day) or placebo treatment for 27 days, were analyzed. At 15 days after washout, the treatments were crossed over. The primary outcome measure was the changes in the Rush Dyskinesia Rating Scale (RDRS) during each treatment period. The secondary outcome measures were changes in the Unified Parkinson's Disease Rating Scale part IVa (UPDRS-IVa, dyskinesias), part IVb (motor fluctuations), and part III (motor function).

Results: RDRS improved in 64% and 16% of patients treated with amantadine or placebo, respectively, with significant differences between treatments. The adjusted odds-ratio for improvement by amantadine was 6.7 (95% confidence interval, 1.4 to 31.5). UPDRS-IVa was improved to a significantly greater degree in amantadine-treated patients [mean (SD) of 1.83 (1.56)] compared with placebo-treated patients [0.03 (1.51)]. However, there were no significant effects on UPDRS-IVb or III scores.

Conclusions: Results from the present study demonstrated that amantadine exhibited efficacious effects against dyskinesias in 60-70% of patients.

Trial registration: UMIN Clinical Trial Registry UMIN000000780.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Dr. Sawada is funded by the grants-in-aid from the National Hospital Organization and received honoraria for lectures from Novartis Pharma, GlaxoSmithKline and Boehringer Ingelheim.

Figures

Figure 1
Figure 1. Study design and flow diagram.
Top, cross-over scheme of patients randomly allocated to Arms 1 and 2. In Arm 1, amantadine was increased from 100 mg to 300 mg every 7 days, and decreased every 3 days. At 15 days after washout, placebo was administered in a similar manner. In Arm 2, placebo was increased every 7 days and decreased every 3 days, which was followed by a similar washout period and amantadine was then administered in the same fashion. Bottom, flow diagram of patients in the study.
Figure 2
Figure 2. Score changes in RDRS, UPDRS-IVa (dyskinesias), IVb (motor fluctuation), and III (motor disturbance) following amantadine and placebo treatment.
Following amantadine treatment, RDRS scores improved in 64% of participants (−2 points in 27%, and −1 point in 37%), but remained unchanged in 37% of participants. RDRS scores improved in 16% of participants, but did not improve in 84%, following placebo treatment (A). UPDRS-IVa scores significantly improved following amantadine treatment (B). In contrast, UPDRS-IVb and III scores did not improve following treatment with amantadine or placebo (C, D). Data are plotted as scattered diagrams and bars represent means with standard deviations of raw data.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:10–15. - PMC - PubMed
    1. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol. 2009;8:67–81. - PubMed
    1. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005;20:224–230. - PubMed
    1. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain. 2007;130:1819–1833. - PubMed
    1. Corvol JC, Muriel MP, Valjent E, Feger J, Hanoun N, et al. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci. 2004;24:7007–7014. - PMC - PubMed

Publication types